Address: Peti #8, Wisma Selangor Dredging, 5th Floor, South Block, 142-A, Jalan Ampang, 50450 Kuala Lumpur, Malaysia
Tel: +603 2161 4181
Ranbaxy Laboratories Limited (Ranbaxy), India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 46 countries, world-class manufacturing facilities in 7 countries and serves customers in over 125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.
Ranbaxy’s mission is ‘To become a Research-based International Pharmaceutical Company’. The Company is driven by its vision to ‘Achieve significant business in proprietary prescription products by 2012 with a strong presence in developed markets’.
Recognized as a leading manufacturer, Ranbaxy Malaysia was set up as a wholly owned subsidiary in June 1984.
With its excellent sales and marketing team, who are experienced and well versed with the industry, the company today has strong brand recognition amongst the General Practitioners, Government Hospitals and Retail Pharmacy sector. The marketing and distribution of Ranbaxy’s products is also undertaken for Schwarz Pharma and Desitin, Germany and Pharmascience, Canada.
Products and services
Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales.
Ranbaxy’s diverse product basket of over 5,000 SKUs available in over 125 countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare trends project that the chronic treatment segments will outpace the acute treatment segments, primarily driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments.
Top 10 Products (2009)
• Ciprofloxacin and Combinations
• Amoxycillin and Combinations
• Ketorolac Tromethamine
• Loratadine and Combinations
• Atorvastatin and Combinations